Angie Risley - Smith Nephew Non-Executive Director
| SNNUF Stock | USD 11.66 0.73 5.89% |
Director
Ms. Angie Risley is NonExecutive Independent Director of the company effective 18 September 2017. She appointed Chair of the Remuneration Committee on 12 April 2018. Career and experience After graduating from Exeter University, and completing a 1year personnel management programme, Angie joined the United Biscuits graduate scheme. After working in various different HR roles she joined Pizza Hut Ltd as Human Resources Director, a joint venture between PepsiCo and Whitbread plc. After five years she joined Whitbread, becoming Executive Director on the plc board responsible for HR and Corporationrationrate Social Responsibility in 2004. Between 20072013 she was the Group HR Director for Lloyds Banking Group, joining J Sainsbury plc as Group HRD in January 2013. Over the years, Angie was a member of the Low Pay Commission and has held a number of NonExecutive Directorships with Biffa plc, Arriva and Serco Group plc, and now Smith Nephew. At Serco she was the Chair of the Remuneration Committee. Previously she has attended Remuneration Committees of Whitbread, Lloyds Banking Group, Arriva and attends Sainsburys today. She is also a NonExecutive Director on the Sainsburys Bank Board. Skills and competencies Angie is a wellregarded FTSE 100 Human Resources Director, proven NonExecutive Director and Remuneration Committee Chair. She has gained experience in a wide range of sectors, including a regulated environment. This diversity of experience is welcomed by the Board and the Remuneration Committee. Angie is also an additional resource and sounding board for Smith Nephews own internal Human Resources function. since 2017.
| Age | 59 |
| Tenure | 7 years |
| Phone | 44 1923 477 100 |
| Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has return on total asset (ROA) of 0.0425 % which means that it generated a profit of $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0925 %, meaning that it generated $0.0925 on every $100 dollars invested by stockholders. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Martin Maxwell | Integer Holdings Corp | 62 | |
| Martha Aronson | CONMED | 53 | |
| Shirley Jackson | Medtronic PLC | 70 | |
| Amy Wendell | Axogen Inc | 57 | |
| Nathaniel Woodson | Paragon 28 | 72 | |
| David Pelizzon | Orthopediatrics Corp | 62 | |
| Thomas Bowers | Paragon 28 | 70 | |
| Elizabeth Nabel | Medtronic PLC | 69 | |
| Andrea Saia | LivaNova PLC | 60 | |
| John Workman | CONMED | 69 | |
| Quentin Blackford | Axogen Inc | 39 | |
| Craig Arnold | Medtronic PLC | 60 | |
| Robert Pozen | Medtronic PLC | 71 | |
| Peter Munson | Orthopediatrics Corp | 49 | |
| Kristina Wright | Paragon 28 | 47 | |
| Joseph Mandato | Axogen Inc | 70 | |
| George Philip | Paragon 28 | 67 | |
| Jean Hobby | Integer Holdings Corp | 60 | |
| Dirk Kuyper | CONMED | 61 | |
| Marc Stapley | Glaukos Corp | 50 | |
| Randall Hogan | Medtronic PLC | 64 | |
Management Performance
| Return On Equity | 0.0925 | |||
| Return On Asset | 0.0425 |
Smith Nephew plc Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Namal Nawana, CEO, Executive Director | ||
| Michael Friedman, Non-Executive Independent Director | ||
| Diogo MoreiraRato, President - Europe and Canada | ||
| Alison Parkes, Chief Officer | ||
| Skip Kiil, President - Orthopedics | ||
| Erik Engstrom, Non-Executive Director | ||
| Deepak Nath, CEO Director | ||
| Matthew Stober, President - Global Operations | ||
| Marc Owen, Non-Executive Director | ||
| AnneFrancoise Nesmes, CFO Director | ||
| Helen Barraclough, Company Counsel | ||
| Rodrigo Bianchi, President IRAMEA | ||
| Brian Larcombe, Senior Independent Non-Executive Director | ||
| Elga Lohler, Chief Human Resource Officer | ||
| Bradley Cannon, Sports Orthopaedics | ||
| Gunthorp Oie, IR Contact Officer | ||
| Roland Diggelmann, Non-Executive Director | ||
| Helen Maye, Chief Human Resources Officer | ||
| Vinita Bali, Non-Executive Director | ||
| Simon Fraser, President - Advanced Wound Management | ||
| Massimiliano Colella, President Europe - Middle East and Africa | ||
| Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee | ||
| Graham Baker, CFO, Executive Director | ||
| Cathy ORourke, Chief Legal and Compliance Officer | ||
| Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
| Joe Metzger, VP Communications | ||
| Cyrille Petit, Chief Corporate Development Officer | ||
| Julie Brown, CFO, Director and Member of Disclosures Committee | ||
| Glenn Warner, President - Advanced Wound Management | ||
| Robin Freestone, Non-Executive Director | ||
| Paul Connolly, Pres Operations | ||
| Virginia Bottomley, Non-Executive Independent Director | ||
| Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
| Angie Risley, Non-Executive Director | ||
| Mark Gladwell, President - Global Operations | ||
| Andrew Swift, VP Relations | ||
| Vasant Padmanabhan, President - Research & Development | ||
| Michael Frazzette, President - Advanced Surgical Devices | ||
| Joseph Papa, Non-Executive Independent Director | ||
| Ingeborg Oie, VP, Investor Relations | ||
| Susan Swabey, Company Secretary | ||
| Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
| Philip Cowdy, Chief Officer | ||
| Gordon Howe, President of Global Operations | ||
| John Campo, Chief Legal Officer | ||
| Brad Cannon, President Europe and Canada | ||
| Ian Barlow, Non-Executive Independent Director | ||
| Catheryn ORourke, Chief Legal Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0925 | |||
| Return On Asset | 0.0425 | |||
| Profit Margin | 0.1 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 14.08 B | |||
| Shares Outstanding | 873.35 M | |||
| Shares Owned By Insiders | 0.17 % | |||
| Shares Owned By Institutions | 52.60 % | |||
| Price To Earning | 23.41 X | |||
| Price To Book | 2.12 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Smith Pink Sheet analysis
When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |